Luis F. Oñate-Ocaña

Prof. Luis F. Oñate-Ocaña

Instituto Nacional de Cancerología, Tlalpan, Mexico
orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 December 2006 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
LOLuis F. Oñate-Ocaña
Luis F. Oñate-Ocaña
VAVincenzo Aiello-Crocifoglio
Vincenzo Aiello-Crocifoglio
DGDolores Gallardo-Rincón
Dolores Gallardo-Rincón
RGRoberto Herrera Goepfert
Roberto Herrera Goepfert
RBRocío Brom-Valladares
Rocío Brom-Valladares
AMAlejandro Mohar-Betancourt
Alejandro Mohar-Betancourt

1 January 2009 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
LOLuis F. Oñate-Ocaña
Luis F. Oñate-Ocaña
AAAlberto Alcántara-Pilar
Alberto Alcántara-Pilar
DVDiana Vilar-Compte
Diana Vilar-Compte
GGGabriela García-Hubard
Gabriela García-Hubard
EREdith Rojas-Castillo
Edith Rojas-Castillo
VAVincenzo Aiello-Crocifoglio
Vincenzo Aiello-Crocifoglio

22 July 2011 in Psycho-Oncology
Verified
Journal Article
Closed access
PDF file
YSYolanda Suárez‐Del‐Real
Yolanda Suárez‐Del‐Real
SASilvia Allende‐Pérez
Silvia Allende‐Pérez
AAAraceli Alférez‐Mancera
Araceli Alférez‐Mancera
RRRosa Bertha Rodríguez
Rosa Bertha Rodríguez
SJSilvia Jiménez‐Toxtle
Silvia Jiménez‐Toxtle
LOLuis F. Oñate-Ocaña
Luis F. Oñate-Ocaña

1 October 2013 in BMC Cancer
Verified
Journal Article
Open access
PDF file
RGRoberto Herrera Goepfert
Roberto Herrera Goepfert
TVTeresa Vela-Chávez
Teresa Vela-Chávez
ACA Carrillo-Garcia
A Carrillo-Garcia
MLMarcela Lizano
Marcela Lizano
AAAlfredo Amador-Molina
Alfredo Amador-Molina
RHRita Sotelo-Regil Hallmann
Rita Sotelo-Regil Hallmann
Metaplastic carcinoma, an uncommon subtype of breast cancer, is part of the spectrum of basal-like, triple receptor-negative breast carcinomas. The present study examined 20 surgical specimens of metaplastic breast carcinomas, for the presence of high-risk Human papillomavirus (HPV), which is suspected to be a potential carcinogenic agent for breast carcinoma.

8 May 2019 in Cancer Medicine
Verified
Journal Article
Open access
PDF file
JLJulissa Luvián‐Morales
Julissa Luvián‐Morales
SGSagrario González‐Trejo
Sagrario González‐Trejo
JCJosé F. Carrillo
José F. Carrillo
RGRoberto Herrera Goepfert
Roberto Herrera Goepfert
VAVincenzo Aiello‐Crocifoglio
Vincenzo Aiello‐Crocifoglio
LOLuis F. Oñate-Ocaña
Luis F. Oñate-Ocaña
Background: The TNM classification does not completely reflect the prognosis of patients with colorectal cancer (CRC). Several clinical factors have been used to increase its prognostic value, but factors pertaining to the patient's immunonutritional status have not usually been addressed. The aim of this study is to evaluate the role of Prognostic nutritional index (PNI) and other well‐known prognostic factors by multivariate analysis in a cohort of patients with CRC.Methods: This is a retrospective cohort study of consecutive patients with CRC managed in a cancer center between January 1992 and December 2016. Cox's model was used to define the association of the PNI and other factors with Overall survival (OS).Results: A total of 3301 patients were included: 47.7% were female and 52.3% were male, with a mean age of 58.7 years. By bivariate analysis, PNI was strongly associated with OS (Risk ratio [RR] 0.968, 95% Confidence interval [CI] 0.962‐0.974; P < 0.001). On multivariate analysis, PNI was an independent explanatory variable (as continuous variable and as categorized variable; RR 0.732, 95% CI 0.611‐0.878; RR 0.656, 95% CI 0.529‐0.813 and RR 0.646, 95% CI 0.521‐0.802, for quintiles 2, 3, and 4‐5, respectively); a biological gradient effect was demonstrated. The final prognostic model included PNI, location of the neoplasia in the colorectum, basal hemoglobin, lymphocyte count, neutrophil/lymphocyte ratio, platelet/lymphocyte ratio, TNM stage, differentiation degree, R classification, and postoperative complications.Conclusions: PNI is a significant and independent prognostic factor in patients with CRC. Its prognostic value adds precision to the TNM staging system including specific subgroups of patients with CRC; it should be evaluated in prospective clinical studies.

1 April 2017 in Medicine
Verified
Journal Article
Open access
PDF file
SGSagrario González-Trejo
Sagrario González-Trejo
JCJosé F. Carrillo
José F. Carrillo
DCD. Darlene Carmona-Herrera
D. Darlene Carmona-Herrera
PBPatricia Baz-Gutiérrez
Patricia Baz-Gutiérrez
RGRoberto Herrera Goepfert
Roberto Herrera Goepfert
LOLuis F. Oñate-Ocaña
Luis F. Oñate-Ocaña
The aim of the present study was to define the prognostic role of baseline serum albumin (BSA) in colorectal cancer (CRC) across tumor–node–metastasis (TNM) stages and other well defined prognostic factors. Many prognostic models in medicine employ BSA to define or refine treatments in very specific settings; in CRC, BSA has been found to be a prognostic factor as well. A retrospective cohort study of consecutive patients with CRC demonstrated by biopsy, who attended a cancer center during a 7-year period. Multivariate analysis was utilized to define prognostic factors associated with overall survival (OS) employing the Cox model. In this retrospective cohort study, 1465 patients were included; 46.6% were females and 53.4% males (mean age, 59.1 years). Mean BSA was inversely correlated with TNM stages. By multivariate analysis, it was an independent explanatory variable. TNM stages, “R” classification, age, lymphocyte count, neutrophil/platelet ratio, neutrophil/lymphocyte ratio, platelet/lymphocyte ratio, postoperative morbidity, and BSA were independently associated with OS. Morbidities, surgery type, chemotherapy, and radiotherapy were considered confounders after adjusting by TNM stages. BSA is a significant and independent prognostic factor in patients with CRC, and its effect is maintained across TNM strata and other well known clinical prognostic factors. It can be easily used in prognostic models and should be employed to stratify prognosis in therapeutic randomized clinical trials.